与直接抗病毒药物应用相关的HCV/HBV双重感染的特点及其诊治管理

于乐成; 范晔; 李平

doi:10.3969/j.issn.1001-5256.2018.02.004

与直接抗病毒药物应用相关的HCV/HBV双重感染的特点及其诊治管理

DOI: 10.3969/j.issn.1001-5256.2018.02.004

南京中医药大学附属八一医院全军肝病中心

详细信息

中图分类号: R512.62;R512.63
计量
- 文章访问数: 2307
- HTML全文浏览量: 10
- PDF下载量: 485
- 被引次数: 0
出版历程
- 收稿日期: 2018-01-18
- 出版日期: 2018-02-20

Features and management of patients with hepatitis C virus/hepatitis B virus dual infection associated with the application of direct-acting antiviral agents

Liver Disease Center of PLA, Bayi Hospital, Nanjing University of Chinese Medicine

摘要

摘要:
HCV和HBV的双重感染（DI）具有不同于单一HCV或HBV感染的特殊临床、免疫学和病毒学特点,为临床诊治和管理带来了诸多挑战。在应用直接抗病毒药物（DAA）有效控制HCV感染的同时,可能导致HBV的激活和乙型肝炎的发作甚至肝衰竭。在抗HCV治疗的同时,根据不同的HCV/HBV-DI状态选用合适的抗HBV治疗和随访管理策略至关重要。
- 肝炎病毒属 /
- 肝炎病毒,乙型 /
- 重叠感染 /
- 诊断 /
- 治疗
Abstract:
Dual infection with hepatitis C virus (HCV) and hepatitis B virus (HBV) has significantly different clinical, immunological, and virological features from single infection with HCV or HBV, which brings various challenges to clinical diagnosis/treatment and management.Direct-acting antiviral agents used for effective control of HCV infection may cause HBV activation, onset of hepatitis B, and even liver failure.Therefore, during the antiviral treatment of HCV infection, it is of great importance to select appropriate anti-HBV therapy and follow-up management strategies based on the status of HCV/HBV dual infection.
- hepacivirus /
- hepatitis B virus /
- superinfection /
- diagnosis /
- therapy

HTML全文

参考文献(22)

[1]YAN LB, RAO HY, MA YJ, et al.Hepatitis B virus infection in Chinese patients HCV infection:prevalence, clinical characteristics, viral interactions and host genotypes:a nationwide cross-sectional study[J].BMJ Open, 2016, 6 (10) :e012016.

[2]YU G, CHI X, WU R, et al.Replication inhibition of hepatitis B virus and hepatitis C virus in coinfected patients in Chinese population[J].PLo S One, 2015, 10 (9) :e0139015.

[3]STANAWAY JD, FLAXMAN AD, NAGHAVI M, et al.The global burden of viral hepatitis from 1990 to 2013:findings from the Global Burden of Disease Study 2013[J].Lancet, 2016, 388 (10049) :1081-1088.

[4]AASLD/IDSA HCV Guidance Panel.Hepatitis C guidance:recommendations for testing, managing, and treating adults infected with hepatitis C virus[J].Hepatology, 2015, 62 (3) :932-954.

[5]ZHANG N, XU CJ, YU WY, et al.Current status and research progress in HBV/HCV co-infection[J].Int J Dig Dis, 2015, 35 (3) :190-193. (in Chinese) 张宁, 徐成军, 于伟燕, 等.HBV/HCV重叠感染的现状与研究进展[J].国际消化病杂志, 2015, 35 (3) :190-193.

[6]JAMMA S, HUSSAIN G, LAU DT.Current concepts of HBV/HCV coinfection:coexistence, but not necessarily in harmony[J].Curr Hepat Rep, 2010, 9 (4) :260-269.

[7]CHEN YS, LI L, CUI FQ, et al.A sero-epidemiological study on hepatitis C in China[J].Chin J Epidemiol, 2011, 32 (9) :888-891.

[8]LOK AS, Mc MAHON BJ.Chronic hepatitis B[J].Hepatology, 2007, 45 (2) :507-539.

[9]FUKUDA R, ISHIMURA N, NIIGAKI M, et al.Serologically silent hepatitis B virus coinfection in patients with hepatitis C virusassociated chronic liver disease:clinical and virological significance[J].J Med Virol, 1999, 58 (3) :201-207.

[10]WANG C, JI D, CHEN J, et al.Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents[J].Clin Gastroenterol Hepatol, 2017, 15 (1) :132-136.

[11]LIU CJ, CHEN PJ, CHEN DS.Dual chronic hepatitis B virus and hepatitis C virus infection[J].Hepatol Int, 2009, 3 (4) :517-525.

[12]KONDO Y, UENO Y, NINOMIYA M, et al.Sequential immunological analysis of HBV/HCV co-infected patients during PegIFN/RBV therapy[J].J Gastroenterol, 2012, 47 (12) :1323-1335.

[13]WIEGAND SB, JAROSZEWICZ J, POTTHOFF A, et al.Dominance of HCV is associated with lower quantitative HBs Ag and higher serum interferon-gamma-induced protein 10 levels in HBV/HCV-coinfected patients[J].Clin Microbiol Infect, 2015, 21 (7) :710.e1-e9.

[14]MEISSNER EG, WU D, OSINUSI A, et al.Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome[J].J Clin Invest, 2014, 124 (8) :3352-3363.

[15]CHEN G, WANG C, CHEN J, et al.Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents:a systematic review and meta-analysis[J].Hepatology, 2017, 66 (1) :13-26.

[16]SAGNELLI E, COPPOLA N, MESSINA V, et al.HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course[J].Hepatology, 2002, 36 (5) :1285-1291.

[17]POLLICINO T, SQUADRITO G, CERENZIA G, et al.Hepatitis B virus maintains its pro-ncogenic properties in the case of occult HBV infection[J].Gastroenterology, 2004, 126:102-110.

[18]LIU CJ, CHU YT, SHAU WY, et al.Treatment of patients with dual hepatitis C and B by peginterferonαand ribavirin reduced risk of hepatocellular carcinoma and mortality[J].Gut, 2014, 63 (3) :506-514.

[19]UYANIKOGLU A, AKYUZ F, BARAN B, et al.Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C[J].Clin Res Hepatol Gastroenterol, 2013, 37 (5) :485-490.

[20]HORNER SM, GALE M Jr.Regulation of hepatic innate immunity by hepatitis C virus[J].Nat Med, 2013, 19 (7) :879-888.

[21]European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol, 2017, 67 (2) :370-398.

[22]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2016[J].J Hepatology, 2017, 66 (1) :153-194.

施引文献

资源附件(0)

访问统计